BrazilTuberculosis profile
Population  2014 206 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5.3 (4.9–5.7) 2.6 (2.4–2.7)
Mortality (HIV+TB only) 2.4 (1.8–3.2) 1.2 (0.87–1.6)
Prevalence  (includes HIV+TB) 110 (51–180) 52 (25–89)
Incidence  (includes HIV+TB) 90 (86–95) 44 (42–46)
Incidence (HIV+TB only) 16 (14–17) 7.6 (6.9–8.4)
         
Case detection, all forms (%) 82 (78–86)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.4 (1–1.8) 7.5 (5.7–9.9)
MDR-TB cases among notified pulmonary
TB cases
820 (590–1 100) 950 (720–1 300)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 41 120   3 602
Pulmonary, clinically diagnosed 17 801   1 488
Extrapulmonary 9 479   480
       
Total new and relapse 73 970    
Previously treated, excluding relapses 7 542    
Total cases notified 81 512    
Among 73 970 new and relapse cases:
2 368 (3%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB     15 344
Laboratory-confirmed RR-/MDR-TB cases     702
Patients started on MDR-TB treatment ***     702
TB/HIV 2014 Number (%)
TB patients with known HIV status 56 981 (70)
HIV-positive TB patients 9 578 (17)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 37 540  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (72) 76 543
Previously treated cases, excluding relapse, registered in 2013 (38) 6 945
HIV-positive TB cases, all types, registered in 2013 (46) 9 460
RR-/MDR-TB cases started on second-line treatment in 2012 (51) 825
XDR-TB cases started on second-line treatment in 2012 (25) 24
Laboratories 2014  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 7.9
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 48
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 77
% Funded domestically 72%
% Funded internationally <1%
% Unfunded 27%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-30 Data: www.who.int/tb/data